Flurbiprofen sustained‐release in OA knee

Boston, P F; Grayson, Martin; Hazelman, B L; Matts, S. G. Flavell; Coutellier, P; Franchimont, P; Moor, M De; Mortier, G; Rosselle, N; Goiethe, H S

doi:10.1111/j.1742-1241.1988.tb08507.x

Cited by 4 publications

(2 citation statements)

References 1 publication

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Results from a short‐term study in general practice (four weeks' treatment) were described in the first paper 1 , and the sustained‐release formulation showed similar overall efficacy and tolerability to that of the standard formulation, but with a slightly greater relief of night pain and morning stiffness. The second paper described results in patients with osteoarthritis of the knee 2 , and the sustained‐release formulation was also observed to have similar efficacy and tolerability to that of the standard formulation.…”

Section: Introductionmentioning

confidence: 97%

A long‐term study of flurbiprofen sustained‐release

Anderson

et al. 1988

Int J Clinical Practice

View full text Add to dashboard Cite

One hundred and twenty patients with arthritis entered a long-term open study of flurbiprofen sustained-rele ase and were assessed at intervals up to 48 weeks. Thirty-seven patients completed 48 weeks, 61 completed at least 24 weeks and 105 at least four weeks of treatment.On the investigator's assessment at 24 weeks, 36 (59 per cent) of 61 patients improved or became well, whilst at 48 weeks, 23 (62 per cent) of 37 patients fell into this category. The median change for quantitative measures of efficacy showed an improvement from that at baseline.Sixty-nine patients (58 per cent) experienced adverse events during the study. Of these, 46 patients (38 per cent) experienced gastrointestinal events. Thirty-three patients withdrew from the study due to adverse events. A fall in mean haemoglobin of 0.6 g/dl occurred over 48 weeks, but the incidence of positive faecal occult blood tests was low and negative results were obtained in most cases, even when haemoglobin levels had fallen.It was concluded that the sustained-rele ase formulation appears to be tolerated satisfactorily over a long time period. It has the advantage of once a day therapy.

show abstract

Section: Introductionmentioning

confidence: 97%

A long‐term study of flurbiprofen sustained‐release

Anderson

et al. 1988

Int J Clinical Practice

View full text Add to dashboard Cite

show abstract

“…The present investigation was designed to examine efficacy and tolerability in comparison with the standard marketed formulation in a short study in general practice. The second paper describes a study in patients with OA of the knee 3 , whilst results of long‐term treatment are described in the third paper 4 .…”

Section: Introductionmentioning

confidence: 99%

A general practice study of flurbiprofen sustained‐release

Constad²

1988

Int J Clinical Practice

View full text Add to dashboard Cite

A comparison of upper gastrointestinal mucosal damage by standard and delayed‐release indomethacin

Swift

Arnold²,

Williams

et al. 1992

Aliment Pharmacol Ther

View full text Add to dashboard Cite

S U M M A R YForty-five patients taking long-term indomethacin and with endoscopic erosions or superficial ulcers in the oesophagus, stomach or duodenal bulb were randomized in a double-blind study to continue with standard indomethacin or receive a ' delayed-release' formulation. This consisted of microgranules of indomethacin coated with an acrylic resin, Eudragit L, which releases drug in the small intestine. Endoscopy was repeated after 8 weeks and biopsies taken on both occasions. Changes in endoscopic lesions and histological appearances were similar in both groups, although mucosal erythema was less in those given Eudragit L indomethacin. Systemic, rather than topical, effects of indomethacin may therefore be responsible for persistence of gastro-duodenal mucosal lesions in these patients. There is reason to question the clinical practice of using expensive, delayed-release preparations.

show abstract

Flurbiprofen sustained‐release in OA knee

Cited by 4 publications

References 1 publication

A long‐term study of flurbiprofen sustained‐release

A long‐term study of flurbiprofen sustained‐release

A general practice study of flurbiprofen sustained‐release

A comparison of upper gastrointestinal mucosal damage by standard and delayed‐release indomethacin

Contact Info

Product

Resources

About